Cancer after spinal fusion: The role of bone morphogenetic protein

Neurosurgery

Volumn 73, Issue 3, 2013, Pages 440-449

  Lad, Shivanand P ^a   Bagley, Jacob H ^a   Karikari, Isaac O ^a   Babu, Ranjith ^a   Ugiliweneza, Beatrice ^b   Kong, Maiying ^b   Isaacs, Robert E ^a   Bagley, Carlos A ^a   Gottfried, Oren N ^a   Patil, Chirag G ^c,d   Boakye, Maxwell ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c University of Louisville School of Medicine   (United States)

^d Maxine Dunitz Neurosurgical Institute   (United States)

Author keywords

BMP; Bone morphogenetic protein; Cancer; Complication; Fusion; Pseudarthrosis; Spine

Indexed keywords

BONE MORPHOGENETIC PROTEIN;

ADULT; ARTICLE; BENIGN TUMOR; CANCER RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG INDUCED DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; NERVOUS SYSTEM TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPINE FUSION;

ADULT; AGED; BONE MORPHOGENETIC PROTEINS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; SPINAL FUSION;

EID: 84883298054     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0000000000000018     Document Type: Article

References (77)

1. Weinstein JN, Lurie JD, Olson PR, Bronner KK, Fisher ES. United States' trends and regional variations in lumbar spine surgery: 1992-2003. Spine (Phila Pa 1976). 2006;31(23):2707-2714. (Pubitemid 44679601)
2. Fischgrund JS, Mackay M, Herkowitz HN, Brower R, Montgomery DM, Kurz LT. 1997 Volvo Award winner in clinical studies: degenerative lumbar spondylolisthesis with spinal stenosis: a prospective, randomized study comparing decompressive laminectomy and arthrodesis with and without spinal instrumentation. Spine (Phila Pa 1976). 1997;22(24):2807-2812. (Pubitemid 28070625)
3. Fritzell P, Hägg O, Wessberg P, Nordwall A; Swedish Lumbar Spine Study Group. Chronic low back pain and fusion: a comparison of three surgical techniques: a prospective multicenter randomized study from the Swedish lumbar spine study group. Spine (Phila Pa 1976). 2002;27(11):1131-1141. (Pubitemid 34596329)
4. Zhou ZJ, Zhao FD, Fang XQ, Zhao X, Fan SW. Meta-analysis of instrumented posterior interbody fusion versus instrumented posterolateral fusion in the lumbar spine. J Neurosurg Spine. 2011;15(3):295-310.
5. Raizman NM, O'Brien JR, Poehling-Monaghan KL, Yu WD. Pseudarthrosis of the spine. J Am Acad Orthop Surg. 2009;17(8):494-503.
6. Kornblum MB, Fischgrund JS, Herkowitz HN, Abraham DA, Berkower DL, Ditkoff JS. Degenerative lumbar spondylolisthesis with spinal stenosis: a prospective long-term study comparing fusion and pseudarthrosis. Spine (Phila Pa 1976). 2004;29(7):726-733; discussion 733-734. (Pubitemid 38437520)
7. Martin BI,Mirza SK, Comstock BA, Gray DT, Kreuter W, Deyo RA. Reoperation rates following lumbar spine surgery and the influence of spinal fusion procedures. Spine (Phila Pa 1976). 2007;32(3):382-387. (Pubitemid 46197482)
8. Adogwa O, Parker SL, Shau D, et al. Long-term outcomes of revision fusion for lumbar pseudarthrosis: clinical article. J Neurosurg Spine. 2011;15(4):393-398.
9. Parker SL, Shau DN, Mendenhall SK, McGirt MJ. Factors influencing 2-year health care costs in patients undergoing revision lumbar fusion procedures. J Neurosurg Spine. 2012;16(4):323-328.
10. Brown CW, Orme TJ, Richardson HD. The rate of pseudarthrosis (surgical nonunion) in patients who are smokers and patients who are nonsmokers: a comparison study. Spine (Phila Pa 1976). 1986;11(9):942-943. (Pubitemid 17012173)
11. Hilibrand AS, Fye MA, Emery SE, Palumbo MA, Bohlman HH. Impact of smoking on the outcome of anterior cervical arthrodesis with interbody or strutgrafting. J Bone Joint Surg Am. 2001;83-A(5):668-673.
12. Bono CM, Lee CK. Critical analysis of trends in fusion for degenerative disc disease over the past 20 years: influence of technique on fusion rate and clinical outcome. Spine (Phila Pa 1976). 2004;29(4):455-463; discussion Z5. (Pubitemid 38209722)
13. Christensen FB, Hansen ES, Eiskjaer SP, et al. Circumferential lumbar spinal fusion with Brantigan cage versus posterolateral fusion with titanium Cotrel-Dubousset instrumentation: a prospective, randomized clinical study of 146 patients. Spine (Phila Pa 1976). 2002;27(23):2674-2683. (Pubitemid 35425321)
14. Jorgenson SS, Lowe TG, France J, Sabin J. A prospective analysis of autograft versus allograft in posterolateral lumbar fusion in the same patient: a minimum of 1-year follow-up in 144 patients. Spine (Phila Pa 1976). 1994;19(18):2048-2053. (Pubitemid 24321352)
15. Burkus JK, Dorchak JD, Sanders DL. Radiographic assessment of interbody fusion using recombinant human bone morphogenetic protein type 2. Spine (Phila Pa 1976). 2003;28(4):372-377. (Pubitemid 36232619)
16. Burkus JK, Gornet MF, Schuler TC, Kleeman TJ, Zdeblick TA. Six-year outcomes of anterior lumbar interbody arthrodesis with use of interbody fusion cages and recombinant human bone morphogenetic protein-2. J Bone Joint Surg Am. 2009;91(5):1181-1189.
17. Burkus JK, Transfeldt EE, Kitchel SH, Watkins RG, Balderston RA. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976). 2002;27(21):2396- 2408. (Pubitemid 35266228)
18. Glassman SD, Dimar JR 3rd, Burkus K, et al. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers. Spine (Phila Pa 1976). 2007;32(15): 1693-1698. (Pubitemid 47051857)
19. Smoljanovic T, Siric F, Bojanic I. Six-year outcomes of anterior lumbar interbody arthrodesis with use of interbody fusion cages and recombinant human bone morphogenetic protein-2. J Bone Joint Surg Am. 2010;92(15):2614-2615; author reply 2615-2616.
20. Cahill KS, Chi JH, Groff MW, McGuire K, Afendulis CC, Claus EB. Outcomes for single-level lumbar fusion: the role of bone morphogenetic protein. Spine (Phila Pa 1976). 2011;36(26):2354-2362.
21. Mitka M. Questions about spine fusion product prompt a new process for reviewing data. JAMA. 2011;306(12):1311-1312.
22. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011;11(6):471-491.
23. Carragee EJ, Mitsunaga KA, Hurwitz EL, Scuderi GJ. Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study. Spine J. 2011;11(6):511-516.
24. Choudhry OJ, Christiano LD, Singh R, Golden BM, Liu JK. Bone morphogenetic protein-induced inflammatory cyst formation after lumbar fusion causing nerve root compression. J Neurosurg Spine. 2012;16(3):296-301.
25. Benglis D, Wang MY, Levi AD. A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery. 2008;62(5 suppl 2): ONS423-ONS431; discussion ONS431.
26. Wang H, Liu D, Yang Z, et al. Association of bone morphogenetic protein-2 gene polymorphisms with susceptibility to ossification of the posterior longitudinal ligament of the spine and its severity in Chinese patients. Eur J Spine. 2008;17(7): 956-964.
27. Chen NF, Smith ZA, Stiner E, Armin S, Sheikh H, Khoo LT. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion. J Neurosurg Spine. 2010;12(1):40-46.
28. Joseph V, Rampersaud YR. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine (Phila Pa 1976). 2007;32(25):2885-2890. (Pubitemid 351339361)
29. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine (Phila Pa 1976). 2002;27(16 suppl 1):S40-S48.
30. Owens K, Glassman SD, Howard JM, Djurasovic M, Witten JL, Carreon LY. Perioperative complications with rhBMP-2 in transforaminal lumbar interbody fusion. Eur J Spine. 2011;20(4):612-617.
31. McClellan JW, Mulconrey DS, Forbes RJ, Fullmer N. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech. 2006;19(7):483-486. (Pubitemid 44526745)
32. Mroz TE, Wang JC, Hashimoto R, Norvell DC. Complications related to osteobiologics use in spine surgery: a systematic review. Spine (Phila Pa 1976). 2010;35(9 suppl):S86-S104.
33. Smucker JD, Rhee JM, Singh K, Yoon ST, Heller JG. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976). 2006;31(24):2813-2819. (Pubitemid 44772783)
34. Mindea SA, Shih P, Song JK. Recombinant human bone morphogenetic protein-2-induced radiculitis in elective minimally invasive transforaminal lumbar interbody fusions: a series review. Spine (Phila Pa 1976). 2009;34(14):1480-1484; discussion 1485.
35. Lewandrowski KU, Nanson C, Calderon R. Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases. Spine J. 2007;7(5):609-614. (Pubitemid 47471438)
36. Williams BJ, Smith JS, Fu KM, et al. Does bone morphogenetic protein increase the incidence of perioperative complications in spinal fusion? A comparison of 55,862 cases of spinal fusion with and without bone morphogenetic protein. Spine (Phila Pa 1976). 2011;36(20):1685-1691.
37. Lad SP, Nathan JK, Boakye M. Trends in the use of bone morphogenetic protein as a substitute to autologous iliac crest bone grafting for spinal fusion procedures in the United States. Spine (Phila Pa 1976). 2011;36(4):E274-E281.
38. Ong KL, Villarraga ML, Lau E, Carreon LY, Kurtz SM, Glassman SD. Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila Pa 1976). 2010;35(19):1794-1800.
39. Abd-El-Barr MM, Cox JB, Antonucci MU, Bennett J, Murad GJ, Pincus DW. Recombinant human bone morphogenetic protein-2 as an adjunct for spine fusion in a pediatric population. Pediatr Neurosurg. 2011;47(4):266-271.
40. Hamilton DK, Smith JS, Reames DL,Williams BJ, Chernavvsky DR, Shaffrey CI. Safety, efficacy, and dosing of recombinant human bone morphogenetic protein-2 for posterior cervical and cervicothoracic instrumented fusion with a minimum 2-year follow-up. Neurosurgery. 2011;69(1):103-111; discussion 111.
41. Hamilton DK, Smith JS, Reames DL, Williams BJ, Shaffrey CI. Use of recombinant human bone morphogenetic protein-2 as an adjunct for instrumented posterior arthrodesis in the occipital cervical region: an analysis of safety, efficacy, and dosing. J Craniovertebr Junction Spine. 2010;1(2):107-112.
42. Boden SD. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine (Phila Pa 1976). 2002;27(16suppl 1):S26-S31.
43. Mannion RJ, Nowitzke AM, Wood MJ. Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2: but what is the cost? Spine J. 2011;11(6):527-533.
44. Lindley TE, Dahdaleh NS, Menezes AH, Abode-Iyamah KO. Complications associated with recombinant human bone morphogenetic protein use in pediatric craniocervical arthrodesis. J Neurosurg Pediatr. 2011;7(5):468-474.
45. Food and Drug Administration, Orthopaedic and Rehabilitation Devices Advisory Panel. Executive summary for P050036 Medtronic's AMPLIFY rhBMP-2 Matrix. 2010. Available at: http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/medicaldevices/medicaldevicesadvisorycommittee/ orthopaedicandrehabilitationdevicespanel/ucm220079.pdf.
46. Hansen LG, Chang S. Health Research Data for the Real World: The Marketscan Databases: Thomson Reuters; 2012.
47. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. JAMA. 2005;294(7):797-802. (Pubitemid 41175722)
48. Zhang Z, Fang J, Gillespie C, Wang G, Hong Y, Yoon PW. Age-specific gender differences in in-hospital mortality by type of acute myocardial infarction. Am J Cardiol. 2012;109(8):1097-1103.
49. Cortes JE, Curns AT, Tate JE, et al. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. N Engl J Med. 2011;365(12):1108-1117.
50. Rosenbaum PR, Rubin DB. The central role of propensity scores in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
51. Aronow HD, Novaro GM, Lauer MS, et al. In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis. Arch Intern Med. 2003;163(21):2576-2582. (Pubitemid 37464415)
52. Frolkis JP, Pothier CE, Blackstone EH, Lauer MS. Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med. 2003;348(9):781-790. (Pubitemid 36245754)
53. Zhang Y, Fonarow GC, Sanders PW, et al. A propensity-matched study of the comparative effectiveness of angiotensin receptor blockers versus angiotensinconverting enzyme inhibitors in heart failure patients age $65 years. Am J Cardiol. 2011;108(10):1443-1448.
54. Kendel F, Dunkel A, Müller-Tasch T, et al. Gender differences in health-related quality of life after coronary bypass surgery: results from a 1-year follow-up in propensity-matched men and women. Psychosom Med. 2011;73(3):280-285.
55. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
56. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
57. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43 (11):1130-1139. (Pubitemid 41587600)
58. KimM, Choe S. BMPs and their clinical potentials. BMB Rep. 2011;44(10):619-634.
59. Singh A, Morris RJ. The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev. 2010;21(4):299-313.
60. Liu C, Tian G, Tu Y, Fu J, Lan C, Wu N. Expression pattern and clinical prognostic relevance of bone morphogenetic protein-2 in human gliomas. Jpn J Clin Oncol. 2009;39(10):625-631.
61. Kleeff J, Maruyama H, Ishiwata T, et al. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology. 1999;116(5):1202-1216. (Pubitemid 29203031)
62. Hung TT, Wang H, Kingsley EA, Risbridger GP, Russell PJ. Molecular profiling of bladder cancer: involvement of the TGF-beta pathway in bladder cancer progression. Cancer Lett. 2008;265(1):27-38.
63. Le Page C, Ouellet V, Madore J, et al. Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. Br J Cancer. 2006;94(3):436-445. (Pubitemid 43237567)
64. Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res. 2004;2(3):141-149. (Pubitemid 39030304)
65. Bieniasz M, Oszajca K, Eusebio M, Kordiak J, Bartkowiak J, Szemraj J. The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer. 2009;66(3):319-326.
66. Rothhammer T, Bataille F, Spruss T, Eissner G, Bosserhoff AK. Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene. 2007;26(28):4158-4170. (Pubitemid 46920167)
67. Brubaker KD, Corey E, Brown LG, Vessella RL. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem. 2004;91(1):151-160.
68. Ide H, Yoshida T, Matsumoto N, et al. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res. 1997;57(22):5022- 5027. (Pubitemid 27498113)
69. Soda H, Raymond E, Sharma S, et al. Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anticancer Drugs. 1998;9(4):327-331. (Pubitemid 28241822)
70. Wen XZ, Akiyama Y, Baylin SB, Yuasa Y. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene. 2006;25(18):2666-2673.
71. Kang HW, Walvick R, Bogdanov A Jr. In vitro and in vivo imaging of antivasculogenesis induced by Noggin protein expression in human venous endothelial cells. FASEB J. 2009;23(12):4126-4134.
72. Tang Y, Ye X, Klineberg EO, Curtiss S, Maitra S, Gupta MC. Temporal and spatial expression of BMPs and BMP antagonists during posterolateral lumbar fusion. Spine (Phila Pa 1976). 2011;36(4):E237-E244.
73. Abe E, Yamamoto M, Taguchi Y, et al. Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin. J Bone Miner Res. 2000;15(4):663-673. (Pubitemid 30174020)
74. Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA. Growth factor regulation of fracture repair. J Bone Miner Res. 1999;14(11):1805-1815. (Pubitemid 29521774)
75. Whittle J, Steinberg EP, Anderson GF, Herbert R. Accuracy of Medicare claims data for estimation of cancer incidence and resection rates among elderly Americans. Med Care. 1991;29(12):1226-1236.
76. Kahn LH, Blustein J, Arons RR, Yee R, Shea S. The validity of hospital administrative data in monitoring variations in breast cancer surgery. Am J Public Health. 1996;86(2):243-245. (Pubitemid 26055222)
77. Cooper GS, Yuan Z, Stange KC, Dennis LK, Amini SB, Rimm AA. The sensitivity of Medicare claims data for case ascertainment of six common cancers. Med Care. 1999;37(5):436-444.